Pacira Pharma (PCRX) Misses Q3 EPS by 83c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of ($0.02), $0.83 worse than the analyst estimate of $0.81. Revenue for the quarter came in at $167.5 million versus the consensus estimate of $171.24 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- American Express (AXP) Tops Q3 EPS by 84c, Misses on Revenue, Raises FY Guidance
- Top restaurant stocks to watch, according to Raymond James
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
